Mannkind, Game-Chancer in Sachen Diabetik? (Seite 394)
eröffnet am 11.01.11 13:02:26 von
neuester Beitrag 10.05.24 08:11:18 von
neuester Beitrag 10.05.24 08:11:18 von
Beiträge: 6.836
ID: 1.162.683
ID: 1.162.683
Aufrufe heute: 3
Gesamt: 594.338
Gesamt: 594.338
Aktive User: 0
ISIN: US56400P7069 · WKN: A2DMZL · Symbol: MNKD
4,3200
USD
+0,23 %
+0,0100 USD
Letzter Kurs 11.05.24 Nasdaq
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,8800 | +57,45 | |
| 17,440 | +44,61 | |
| 1,8400 | +26,03 | |
| 4,9500 | +25,32 | |
| 4,0000 | +25,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,965 | -18,48 | |
| 0,7845 | -19,36 | |
| 3,3200 | -22,61 | |
| 0,6785 | -26,19 | |
| 3,3100 | -77,44 |
Beitrag zu dieser Diskussion schreiben
Feedback
http://cnafinance.com/mannkind-mnkd-stock-is-likely-to-climb…
MannKind Corporation (NASDAQ: MNKD)
MannKind is a very interesting stock in my opinion. That's because I've never seen another stock invoke such emotion, debate and passion among traders. Those that are bullish on the stock are die-hard bulls and those that are bearish swear by their opinions. With that said, I'll start by letting you know that I'm a bull. I have been a bull on the stock since last year and I'm glad that I've maintained my opinion. Based on what we've seen from MNKD recently, I don't think bulls will be waiting much longer for gains either. Today, we'll talk about why.
MannKind Is Granted Dual Listing On TAVE
MannKind has been releasing a slew of positive news as of late. Most recently, the company announced last week that the Tel Aviv Stock Exchange has approved a new listing of MNKD common shares. The new listing will be available starting October 28. The company will also remain listed on the NASDAQ global index. This is great news for MNKD as it is likely to broaden the spectrum with regard to investors. Here's what Hakan Edstrom, President and CEO of MannKind had to say during the announcement...
“The new listing also offers an opportunity to expand and diversify our shareholder base by increasing our exposure and improving our accessibility to Israeli investors... This listing is also an extension of the long-standing relationship between our Executive Chairman, Alfred Mann, and the Israeli biotechnology industry, including the Alfred Mann Institute at the Technion.”
This Isn't The Only Good News We've Heard From MNKD Recently
While the dual listing is definitely positive, it's not the only bit of good news we've heard from MannKind recently. In fact, there is quite a bit going on that really halts the concerns of bearish investors. Here are just a few bits of information that you should know...
•Insurance Is Moving In The Right Direction – One of the biggest concerns with regard to MannKind has been sales of what was expected to be a blockbuster drug, Afrezza. Simply put, sales haven't gone as well as most investors would have liked to have seen. Nonetheless, things are starting to fall in line, which will lead to solid sales figures. One of the biggest hurdles has been insurance. At this point, many insurance companies are covering Afrezza, but they are doing so in a tier that does have higher prices to consumers and limitations. Sanofi is currently negotiating with insurance companies to bring Afrezza into tier 2, the tier that will likely lead to incredible sales volume. I recently wrote a post that explains the insurance issue in detail. Find out more about tiers and how negotiations between SNY and insurance companies will lead to climbing Afrezza sales here.
•Advertising Is Beginning – Another primary concern with regard to sales has been advertising. Unfortunately, for the first several months Afrezza was approved, we saw no advertising; helping the bears with regard to the MNKD opinions. Nonetheless, that is changing as well. In fact at a recent presentation, MNKD announced that Sanofi has begun a string of magazine and online advertisements. This will increase consumer awareness, ultimately leading to more sales.
•Prescriptions Are Starting To Head In The Right Direction – If you pay close attention to prescription numbers, it's easy to see that prescriptions for Afrezza are rising. They aren't quite where we'd like to see them, but they are moving up. This is a sign that the inhaled insulin and its advertising is being well-received.
•Regulatory Approval – Finally, while MannKind has received regulatory approval for Afrezza in the United States, they haven't yet received approval abroad. However, approval in Europe and Asia have been in the works for quite some time now, and I'm expecting to see that go through relatively soon.
MannKind Reports Earnings One Week From Today
Finally, MannKind is set to report earnings on Monday, November 2nd. I'm expecting for this to be the next positive catalyst for the stock. While analysts are calling for a loss of $0.06 per share, I don't think that all is being taken into account. The company has worked to reduce expenses, and sales are starting to rise. With that said, I'm expecting to see an earnings beat this quarter.
MannKind Corporation (NASDAQ: MNKD)
MannKind is a very interesting stock in my opinion. That's because I've never seen another stock invoke such emotion, debate and passion among traders. Those that are bullish on the stock are die-hard bulls and those that are bearish swear by their opinions. With that said, I'll start by letting you know that I'm a bull. I have been a bull on the stock since last year and I'm glad that I've maintained my opinion. Based on what we've seen from MNKD recently, I don't think bulls will be waiting much longer for gains either. Today, we'll talk about why.
MannKind Is Granted Dual Listing On TAVE
MannKind has been releasing a slew of positive news as of late. Most recently, the company announced last week that the Tel Aviv Stock Exchange has approved a new listing of MNKD common shares. The new listing will be available starting October 28. The company will also remain listed on the NASDAQ global index. This is great news for MNKD as it is likely to broaden the spectrum with regard to investors. Here's what Hakan Edstrom, President and CEO of MannKind had to say during the announcement...
“The new listing also offers an opportunity to expand and diversify our shareholder base by increasing our exposure and improving our accessibility to Israeli investors... This listing is also an extension of the long-standing relationship between our Executive Chairman, Alfred Mann, and the Israeli biotechnology industry, including the Alfred Mann Institute at the Technion.”
This Isn't The Only Good News We've Heard From MNKD Recently
While the dual listing is definitely positive, it's not the only bit of good news we've heard from MannKind recently. In fact, there is quite a bit going on that really halts the concerns of bearish investors. Here are just a few bits of information that you should know...
•Insurance Is Moving In The Right Direction – One of the biggest concerns with regard to MannKind has been sales of what was expected to be a blockbuster drug, Afrezza. Simply put, sales haven't gone as well as most investors would have liked to have seen. Nonetheless, things are starting to fall in line, which will lead to solid sales figures. One of the biggest hurdles has been insurance. At this point, many insurance companies are covering Afrezza, but they are doing so in a tier that does have higher prices to consumers and limitations. Sanofi is currently negotiating with insurance companies to bring Afrezza into tier 2, the tier that will likely lead to incredible sales volume. I recently wrote a post that explains the insurance issue in detail. Find out more about tiers and how negotiations between SNY and insurance companies will lead to climbing Afrezza sales here.
•Advertising Is Beginning – Another primary concern with regard to sales has been advertising. Unfortunately, for the first several months Afrezza was approved, we saw no advertising; helping the bears with regard to the MNKD opinions. Nonetheless, that is changing as well. In fact at a recent presentation, MNKD announced that Sanofi has begun a string of magazine and online advertisements. This will increase consumer awareness, ultimately leading to more sales.
•Prescriptions Are Starting To Head In The Right Direction – If you pay close attention to prescription numbers, it's easy to see that prescriptions for Afrezza are rising. They aren't quite where we'd like to see them, but they are moving up. This is a sign that the inhaled insulin and its advertising is being well-received.
•Regulatory Approval – Finally, while MannKind has received regulatory approval for Afrezza in the United States, they haven't yet received approval abroad. However, approval in Europe and Asia have been in the works for quite some time now, and I'm expecting to see that go through relatively soon.
MannKind Reports Earnings One Week From Today
Finally, MannKind is set to report earnings on Monday, November 2nd. I'm expecting for this to be the next positive catalyst for the stock. While analysts are calling for a loss of $0.06 per share, I don't think that all is being taken into account. The company has worked to reduce expenses, and sales are starting to rise. With that said, I'm expecting to see an earnings beat this quarter.
http://finance.yahoo.com/news/mannkind-announces-termination…
VALENCIA, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced the return of 9,000,000 shares of its common stock that were loaned to Bank of America, N.A. pursuant to a stock lending agreement dated August 18, 2010. The stock lending agreement was entered into to facilitate the establishment of hedge positions by investors in MannKind's offering Senior Convertible Notes due 2015, which closed on August 24, 2010. The stock lending agreement terminated a specified number of days following the date as of which the entire principal amount of Senior Convertible Notes due 2015 ceased to be outstanding and MannKind had settled all payments and deliveries in respect of such convertible notes, which occurred on August 17, 2015.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
VALENCIA, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced the return of 9,000,000 shares of its common stock that were loaned to Bank of America, N.A. pursuant to a stock lending agreement dated August 18, 2010. The stock lending agreement was entered into to facilitate the establishment of hedge positions by investors in MannKind's offering Senior Convertible Notes due 2015, which closed on August 24, 2010. The stock lending agreement terminated a specified number of days following the date as of which the entire principal amount of Senior Convertible Notes due 2015 ceased to be outstanding and MannKind had settled all payments and deliveries in respect of such convertible notes, which occurred on August 17, 2015.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
http://www.biospace.com/news_story.aspx?StoryID=396223&full=…
October 23, 2015
By Mark Terry, BioSpace.com Breaking News Staff
Rumors are spinning that Sanofi (SNY) has frozen hiring for the sales team for its inhaled insulin product, Afrezza. Sanofi, however, did not confirm when contacted by in-PharmaTechnologist.com.
Matt Pfeffer, chief financial officer of MannKind Corporation (MNKD), Sanofi’s partner and developer of Afrezza, told in-Pharma that Sanofi’s marketing approach was solid. “We have seen no indication that they are faltering in their commitment to the product — quite the contrary, in fact. The only changes [in sales force numbers] I am aware of have been increases. There are certainly people out there with a vested interested in our not succeeding. This would not be the first time misinformation has been circulated about us or about Afrezza.”
Early in 2014, the U.S. Food and Drug Administration (FDA) approved Afrezza, an inhaled form of insulin. Generally speaking, this seemed like a great idea for a product to treat diabetes because it would eliminate the need for needles. Not only do most people not like taking shots, but in some cases they’re very inconvenient depending on lifestyle or work situations.
Sanofi’s part of the relationship with MannKind is commercialization, and hence, negotiations with insurance companies regarding reimbursement and pricing. Which is where Afrezza is apparently running in to what some analysts suspect will be short-term issues.
Insurance companies generally classify drugs in four tiers, 1 through 4. Tier 1 drugs are usually low-priced generic drugs. Tier 2 is typically a preferred brand name prescription drug. Tiers 3 and 4 are, as described by Joshua Rodriguez, founder of CNA Finance, “for higher cost prescription medications and medications that may be deemed to be effective but not the best choice for most patients.”
As Rodriguez points out, MannKind and Sanofi want Afrezza to be in Tier 2. But for most insurance companies, it’s listed in Tier 3. “This means that consumers who would like to try MannKind’s product will have to pay a higher co-pay and possibly deal with restrictions, which is harming sales volume on the treatment.”
This is likely at least part of the reason initial sales of Afrezza have been slow. Rodriguez predicts that the drug will likely get shifted to Tier 2 in 2016, which would be the result of negotiations between Sanofi and insurance companies.
In MannKind’s second quarter earnings report, Hakan Edstrom, chief executive officer of MannKind, said, “…insurance coverage continues to slow the process. At this point, permanent formulary placement decisions have not yet been made by most plans. These decisions are typically made six to 12 months following the launch.”
And as Rodriguez further points out, there are an estimated 28.7 million diabetic patients in the U.S. alone, with reportedly 10 percent of them afraid of shots. So there are — at least — a potential 2.9 million possible customers for Afrezza, although due to work-related issues, that number may be more like 4.2 million. And even for people who are accustomed to injections, it’s unlikely they like shots, and might prefer an inhaled version. The market’s clearly there.
The rumors about the sales force come only a couple weeks after MannKind announced it was laying off workers at its Danbury, Conn. facility. Pfeffer at the time told The News-Times that the cuts were ongoing efforts for “right-sizing the company to reflect anticipated demand and operational needs. These reductions affected all of our sites, both here on the east coast as well as California, and affected all levels of management in the company.”
Possibly Sanofi will reveal more of its plans in its third quarter 2015 results on October 29
October 23, 2015
By Mark Terry, BioSpace.com Breaking News Staff
Rumors are spinning that Sanofi (SNY) has frozen hiring for the sales team for its inhaled insulin product, Afrezza. Sanofi, however, did not confirm when contacted by in-PharmaTechnologist.com.
Matt Pfeffer, chief financial officer of MannKind Corporation (MNKD), Sanofi’s partner and developer of Afrezza, told in-Pharma that Sanofi’s marketing approach was solid. “We have seen no indication that they are faltering in their commitment to the product — quite the contrary, in fact. The only changes [in sales force numbers] I am aware of have been increases. There are certainly people out there with a vested interested in our not succeeding. This would not be the first time misinformation has been circulated about us or about Afrezza.”
Early in 2014, the U.S. Food and Drug Administration (FDA) approved Afrezza, an inhaled form of insulin. Generally speaking, this seemed like a great idea for a product to treat diabetes because it would eliminate the need for needles. Not only do most people not like taking shots, but in some cases they’re very inconvenient depending on lifestyle or work situations.
Sanofi’s part of the relationship with MannKind is commercialization, and hence, negotiations with insurance companies regarding reimbursement and pricing. Which is where Afrezza is apparently running in to what some analysts suspect will be short-term issues.
Insurance companies generally classify drugs in four tiers, 1 through 4. Tier 1 drugs are usually low-priced generic drugs. Tier 2 is typically a preferred brand name prescription drug. Tiers 3 and 4 are, as described by Joshua Rodriguez, founder of CNA Finance, “for higher cost prescription medications and medications that may be deemed to be effective but not the best choice for most patients.”
As Rodriguez points out, MannKind and Sanofi want Afrezza to be in Tier 2. But for most insurance companies, it’s listed in Tier 3. “This means that consumers who would like to try MannKind’s product will have to pay a higher co-pay and possibly deal with restrictions, which is harming sales volume on the treatment.”
This is likely at least part of the reason initial sales of Afrezza have been slow. Rodriguez predicts that the drug will likely get shifted to Tier 2 in 2016, which would be the result of negotiations between Sanofi and insurance companies.
In MannKind’s second quarter earnings report, Hakan Edstrom, chief executive officer of MannKind, said, “…insurance coverage continues to slow the process. At this point, permanent formulary placement decisions have not yet been made by most plans. These decisions are typically made six to 12 months following the launch.”
And as Rodriguez further points out, there are an estimated 28.7 million diabetic patients in the U.S. alone, with reportedly 10 percent of them afraid of shots. So there are — at least — a potential 2.9 million possible customers for Afrezza, although due to work-related issues, that number may be more like 4.2 million. And even for people who are accustomed to injections, it’s unlikely they like shots, and might prefer an inhaled version. The market’s clearly there.
The rumors about the sales force come only a couple weeks after MannKind announced it was laying off workers at its Danbury, Conn. facility. Pfeffer at the time told The News-Times that the cuts were ongoing efforts for “right-sizing the company to reflect anticipated demand and operational needs. These reductions affected all of our sites, both here on the east coast as well as California, and affected all levels of management in the company.”
Possibly Sanofi will reveal more of its plans in its third quarter 2015 results on October 29
Ich frage mich auch die ganze Zeit, woher die genauen Zahlen für TRx und NRx immer kommen und ob die auch wirklich so genau sind...
Auf dem Yahoo Board gefunden:
i read on SA that the weekly Trx & Nrx # s don t include CVS or Express Scripts. CVS is #2 pharmacy, 6,288 stores. real scripts # x 2
Vielleicht sind die wirklichen Zahlen auch viel höher und wir merken das erst bei den Q-Zahlen! Man wird sehen
Auf dem Yahoo Board gefunden:
i read on SA that the weekly Trx & Nrx # s don t include CVS or Express Scripts. CVS is #2 pharmacy, 6,288 stores. real scripts # x 2
Vielleicht sind die wirklichen Zahlen auch viel höher und wir merken das erst bei den Q-Zahlen! Man wird sehen
Antwort auf Beitrag Nr.: 50.928.063 von icebox1977 am 25.10.15 13:50:31dahinter stehen nord und süd.
was sind es derzeit-130.000.000 short?irre.sage mal nackter wahnsinn.
diese woche endlich über 400 nx gerne viel mehr- dann kann sich das bild ändern
es sein denn feuerstein schreibt für uninformierte einen neuen artikelgruß
was sind es derzeit-130.000.000 short?irre.sage mal nackter wahnsinn.
diese woche endlich über 400 nx gerne viel mehr- dann kann sich das bild ändern
es sein denn feuerstein schreibt für uninformierte einen neuen artikelgruß
Trading Spotlight
Norddeutscher Nr.2 meldet sich zum Dienst.Möge den Shorties die News im Halse stecken bleiben!Wer weiß was Al noch für uns parat hält
Antwort auf Beitrag Nr.: 50.921.187 von price-of-success am 23.10.15 20:57:02Das südafrikanisch-griechische Schwabenland auch...
Das natürlich schwäbisch bruddeln muß: so super sen die news dann au wieder net, dass es des rausreißt...
Aber immerhin ein Hoffnungsschimmer, der uns das WE versüßen sollte.
Das natürlich schwäbisch bruddeln muß: so super sen die news dann au wieder net, dass es des rausreißt...
Aber immerhin ein Hoffnungsschimmer, der uns das WE versüßen sollte.
Antwort auf Beitrag Nr.: 50.921.022 von Gangal am 23.10.15 20:31:29Norddeutschland ist ebenfalls vertreten...
Unglaublich hier... Super News und koa Sau hier außer Magnefeld
MannKind (NASDAQ: MNKD) announced that the Tel Aviv Stock Exchange (TASE) has approved the new listing of MannKind's common shares beginning on October 28, 2015 under the ticker symbol MNKD. Based on the current market capitalization, MannKind's shares are anticipated to be included in five TASE equity indexes: TASE's TA-75, TA-100, TA-BlueTech, TA-Tech-Elite and TA-Biomed.
"The new listing also offers an opportunity to expand and diversify our shareholder base by increasing our exposure and improving our accessibility to Israeli investors," said Hakan Edstrom, President and CEO of MannKind. "This listing is also an extension of the long-standing relationship between our Executive Chairman, Alfred Mann, and the Israeli biotechnology industry, including the Alfred Mann Institute at the Technion (Israel Institute of Technology)."
TASE CEO, Yossi Beinart said, "We welcome MannKind to the TASE Dual Listing, and believe that this is a recognition of the Biomed sector's special position at the Tel Aviv Stock Exchange. MannKind has long and strong relations with the Israeli Biomed Sector, via the founder and executive chairman Mr. Alfred E. Mann, one of pioneers of the Biomed sector in the U.S., who has supported developing and commercializing Israeli technologies for many years. We are proud that a company with a market value of more than a billion US dollars chose to join 50 dually-listed companies, as well as the TASE leading indices. Joining TASE entitles MannKind to significant benefits, including added exposure among Israeli investors, extension of the trading duration, investment by Exchange Traded Product vendors and easy access to institutional and retail investors."
Trading Regulations
MannKind's shares will continue to be listed on the Nasdaq Global Market, subject to the rules and regulations of the Nasdaq Global Market applicable to listed companies. Under Israel's Dual Listing Law, U.S.-listed companies may also list on the TASE without any additional regulatory requirements. Investors should note that the trading on the TASE occurs Sunday from 8:30 am to 4:30 pm Israel time and Monday through Thursday from 8:30 am to 5:30 pm Israel time, except on TASE trading holidays, and trading on the Nasdaq Global Market occurs Monday through Friday, 9:30 am to 4:00 pm Eastern Time, except on Nasdaq holidays. The TASE Clearing House is electronically linked to the Depository Trust Company, a subsidiary of the Depository Trust & Clearing Corporation, to automate the cross-border settlement of shares listed on both the TASE and a U.S. Exchange.
http://www.streetinsider.com/Corporate+News//MannKind+%28MNK…" target="_blank" rel="nofollow ugc noopener">
http://www.streetinsider.com/Corporate+News//MannKind+%28MNK…
MannKind (NASDAQ: MNKD) announced that the Tel Aviv Stock Exchange (TASE) has approved the new listing of MannKind's common shares beginning on October 28, 2015 under the ticker symbol MNKD. Based on the current market capitalization, MannKind's shares are anticipated to be included in five TASE equity indexes: TASE's TA-75, TA-100, TA-BlueTech, TA-Tech-Elite and TA-Biomed.
"The new listing also offers an opportunity to expand and diversify our shareholder base by increasing our exposure and improving our accessibility to Israeli investors," said Hakan Edstrom, President and CEO of MannKind. "This listing is also an extension of the long-standing relationship between our Executive Chairman, Alfred Mann, and the Israeli biotechnology industry, including the Alfred Mann Institute at the Technion (Israel Institute of Technology)."
TASE CEO, Yossi Beinart said, "We welcome MannKind to the TASE Dual Listing, and believe that this is a recognition of the Biomed sector's special position at the Tel Aviv Stock Exchange. MannKind has long and strong relations with the Israeli Biomed Sector, via the founder and executive chairman Mr. Alfred E. Mann, one of pioneers of the Biomed sector in the U.S., who has supported developing and commercializing Israeli technologies for many years. We are proud that a company with a market value of more than a billion US dollars chose to join 50 dually-listed companies, as well as the TASE leading indices. Joining TASE entitles MannKind to significant benefits, including added exposure among Israeli investors, extension of the trading duration, investment by Exchange Traded Product vendors and easy access to institutional and retail investors."
Trading Regulations
MannKind's shares will continue to be listed on the Nasdaq Global Market, subject to the rules and regulations of the Nasdaq Global Market applicable to listed companies. Under Israel's Dual Listing Law, U.S.-listed companies may also list on the TASE without any additional regulatory requirements. Investors should note that the trading on the TASE occurs Sunday from 8:30 am to 4:30 pm Israel time and Monday through Thursday from 8:30 am to 5:30 pm Israel time, except on TASE trading holidays, and trading on the Nasdaq Global Market occurs Monday through Friday, 9:30 am to 4:00 pm Eastern Time, except on Nasdaq holidays. The TASE Clearing House is electronically linked to the Depository Trust Company, a subsidiary of the Depository Trust & Clearing Corporation, to automate the cross-border settlement of shares listed on both the TASE and a U.S. Exchange.
http://www.streetinsider.com/Corporate+News//MannKind+%28MNK…" target="_blank" rel="nofollow ugc noopener">
http://www.streetinsider.com/Corporate+News//MannKind+%28MNK…
,
http://finance.yahoo.com/news/inplay-briefing-com-055139997.…Für mich klar, Afrezza steht kurz vor der Zulassung in Israel, oder vielleicht wird die Technosphere Technologie mit TEVA verpartnert?
Durchsuchen
Mannkind, Game-Chancer in Sachen Diabetik?
